Do semaglutide and tirzepatide cause NAION vision loss, and how worried should I be?

The short answer

Regulators confirmed a real but very rare eye risk with semaglutide. The EMA's safety committee concluded NAION — sudden vision loss, usually in one eye — is a very rare side effect of Ozempic, Rybelsus and Wegovy, affecting up to 1 in 10,000 people. The product information now lists it. Tirzepatide has not received the same label change.

Evidence tier: Tier 1 for the regulatory conclusion (EMA/PRAC review of non-clinical, clinical, post-marketing and literature data); Tier 2 for the causal mechanism, which remains uncertain. Educational content, not medical advice.

The key points:

• It's confirmed but very rare — up to 1 in 10,000, the lowest frequency category regulators use.
• The label change is on semaglutide (Ozempic, Rybelsus, Wegovy) — not tirzepatide.
• The action is simple and urgent — sudden vision loss or rapidly worsening eyesight means contact a doctor immediately.
• If NAION is confirmed, semaglutide should be stopped — that's the regulator's own guidance.

What is NAION?

Evidence tier: 2 — established ophthalmology.

NAION stands for non-arteritic anterior ischemic optic neuropathy. In plain terms: the optic nerve head loses its blood supply, and the nerve is damaged. It typically presents as sudden, painless loss of vision in one eye, often noticed on waking, and the vision loss is frequently permanent. It is sometimes described as a "stroke of the optic nerve," which captures the mechanism reasonably well.

NAION is not a new or exotic condition, and it is not unique to GLP-1 drugs. It occurs in the general population, and its established risk factors overlap heavily with the population taking these medications: diabetes, high blood pressure, obesity, sleep apnoea, and a particular optic-disc anatomy sometimes called a "crowded disc." That overlap is precisely what makes the causal question hard, and it's worth holding in mind before assuming the drug is the whole story.

What matters practically is that NAION is a genuine medical emergency in the sense that it needs urgent assessment. There is no reliable treatment to reverse it once established, which is why the guidance centres on rapid evaluation rather than watchful waiting.

What did the regulators actually conclude?

Evidence tier: 1 — formal regulatory review of the full evidence base.

This is where precision matters, because the headlines have been messier than the findings.

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) opened a review in January 2025 into whether semaglutide increases NAION risk. After assessing non-clinical studies, clinical trials, post-marketing surveillance and the published literature, PRAC concluded that NAION is a very rare side effect of semaglutide — with "very rare" being a defined regulatory frequency meaning it may affect up to 1 in 10,000 people taking it (EMA PRAC conclusion). The product information for Ozempic, Rybelsus and Wegovy was updated accordingly (Wegovy product information).

The WHO issued a parallel alert to healthcare professionals about the association, noting that NAION had been very rarely reported with semaglutide across its diabetes, weight-management and cardiovascular-risk indications (WHO alert on semaglutide and NAION). The UK's MHRA issued its own Drug Safety Update in February 2026 with the same substance.

Two things this does not say. It does not say semaglutide commonly causes blindness — "very rare" is the lowest frequency band regulators assign. And it does not establish the biological mechanism; the causal pathway remains uncertain, which is why the finding is framed as an identified side effect rather than a fully explained one.

Does this apply to tirzepatide (Mounjaro/Zepbound)?

Evidence tier: 2 — based on current regulatory status; subject to change.

This is the most common point of confusion in community discussion, and the honest answer is: the regulatory action has been on semaglutide, not tirzepatide. The EMA review, the label update, the WHO alert and the MHRA safety update all concern semaglutide-containing medicines — Ozempic, Rybelsus and Wegovy. Tirzepatide has not received an equivalent NAION label change.

That distinction matters, but so does not over-reading it. "No equivalent label change" is not the same as "proven safe" — an absence of regulatory action can reflect a genuine difference between the drugs, or simply that the evidence base and reporting volume differ. Tirzepatide appears in ongoing litigation discussion around GLP-1 and vision loss, which is a legal process rather than a scientific or regulatory conclusion, and shouldn't be read as either.

The practical upshot is the same whichever drug you're on: sudden vision change is an urgent symptom that warrants immediate medical attention, regardless of which agent you're taking. For the broader side-effect picture, see managing GLP-1 side effects.

What should you actually do?

Evidence tier: 1 — this reflects the regulators' own guidance.

The guidance is refreshingly unambiguous:

• Sudden loss of vision, or rapidly worsening eyesight, while on semaglutide → contact a doctor without delay. UK guidance specifically directs people to attend eye casualty urgently. Do not wait to see if it improves.
• If NAION is confirmed, semaglutide should be stopped. That is the regulator's stated position, and it's a decision for your prescriber to make with you — not something to action unilaterally, and equally not something to delay raising.
• Don't stop your medication out of anxiety alone. A very rare risk has to be weighed against the substantial, well-evidenced benefits of these drugs for weight and metabolic health. Stopping abruptly carries its own consequences, including appetite return and weight regain — see stopping a GLP-1. Raise it with your prescriber rather than deciding alone.
• Flag your risk factors. If you have diabetes, hypertension, sleep apnoea, or a known history of NAION in one eye, that's worth an explicit conversation with your prescriber — and an ophthalmologist's input if you've had NAION before.

Routine eye screening purely because you are taking semaglutide is not currently a standard recommendation, and this article isn't the place to invent one. If you have diabetes, though, you should already be in a retinal screening programme for entirely separate reasons — keep those appointments.

One further point worth understanding, because it causes unnecessary alarm. Blurry vision in the first weeks on a GLP-1 is a common and generally different phenomenon: rapid improvement in blood glucose can transiently change the refractive properties of the lens, producing temporary blurring that settles as levels stabilise. In people with existing diabetic retinopathy, rapid glucose improvement can also cause a temporary worsening before it improves — a long-recognised effect of any intensive glucose-lowering, not something unique to these drugs. Neither of those is NAION. The distinguishing features of NAION are that it is sudden, usually affects one eye, involves actual loss of vision or a missing area of visual field rather than general blurriness, and is painless. Gradual, both-sided blurring that comes and goes is a different conversation from waking up unable to see properly out of one eye — though if you're unsure which you're experiencing, treat it as the urgent one and get it looked at.

Limitations

This is educational content, not medical advice.

• "Very rare" is a defined regulatory frequency (up to 1 in 10,000), not a colloquial reassurance — but it does mean the large majority of users will never encounter this.
• Causality is not fully established. NAION's risk factors overlap heavily with the population taking these drugs, which complicates attribution; regulators identified an association strong enough to label, not a proven mechanism.
• The tirzepatide position may change — regulatory reviews are ongoing across this class, and absence of a label change today is not a permanent safety verdict.
• Litigation is not evidence. Ongoing lawsuits around GLP-1s and vision loss are a legal process and should not be read as scientific conclusion in either direction.
• Any sudden vision change needs a clinician, not an article. Nothing here substitutes for urgent assessment.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

The eye warnings people are seeing are real, and they're specific. Europe's medicines regulator reviewed the full evidence base and concluded that NAION — sudden, usually one-sided, often permanent vision loss — is a very rare side effect of semaglutide, affecting up to 1 in 10,000 people, and the product information for Ozempic, Rybelsus and Wegovy now says so. The WHO and the UK's MHRA issued parallel alerts. Tirzepatide has not had the same label change, though that isn't a clean bill of health either. What this should change for you is small but important: know that sudden vision loss or rapidly worsening eyesight is an urgent symptom requiring immediate medical attention rather than a wait-and-see, and if NAION is confirmed the guidance is to stop semaglutide. What it shouldn't do is panic you off an effective medication over a risk at the very rare end of the scale — that's a conversation for your prescriber, weighed against the benefit you're getting.

Related on this site

• Managing GLP-1 side effects
• Stopping a GLP-1: rebound & weight regain
• Do GLP-1s stop working? Tolerance & plateaus
• GLP-1s & mental health: mood and anxiety
• Our evidence-tier framework

References

• European Medicines Agency (PRAC). NAION concluded a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. EMA PRAC conclusion — the primary regulatory determination and frequency classification.
• European Medicines Agency. Wegovy EPAR product information. Product information PDF — the updated label text.
• World Health Organization. Semaglutide medicines and risk of NAION. WHO alert — international healthcare-professional alert.
• MHRA. Drug Safety Update: semaglutide and NAION, February 2026 — UK guidance directing urgent ophthalmological referral for sudden vision loss.